Technical Analysis for CCXI - ChemoCentryx, Inc.

Grade Last Price % Change Price Change
grade D 10.91 3.90% 0.41
CCXI closed up 3.9 percent on Friday, March 22, 2019, on 1.43 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical CCXI trend table...

Date Alert Name Type % Chg
Mar 22 Crossed Above 20 DMA Bullish 0.00%
Mar 22 Pocket Pivot Bullish Swing Setup 0.00%
Mar 22 Outside Day Range Expansion 0.00%
Mar 21 Fell Below 20 DMA Bearish 3.90%
Mar 20 200 DMA Resistance Bearish -1.00%
Mar 20 Fell Below 50 DMA Bearish -1.00%
Mar 20 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.00%
Mar 20 Inside Day Range Contraction -1.00%
Mar 20 Upper Bollinger Band Touch Strength -1.00%
Mar 19 200 DMA Resistance Bearish -4.38%

Older signals for CCXI ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trials for the treatment of patients with moderate-to-severe Crohn's disease; CCX140 that is in Phase II clinical trials for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company's drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis, an inflammatory disease; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for chronic hepatitis. ChemoCentryx, Inc. has a strategic alliance with Glaxo Group Limited for the discovery and development of small molecule antagonists targeting four defined chemokine and chemo-attractant receptor targets and for advancing them through clinical proof-of-concept. The company was founded in 1997 and is headquartered in Mountain View, California.
Medicine Biopharmaceutical Cancer Immunology Monoclonal Antibodies Autoimmune Diseases Rheumatoid Arthritis Inflammatory Bowel Disease Atopic Dermatitis Immunosuppressants Diabetic Nephropathy Glioblastoma Multiforme Kidney Disease Biotie Therapies Dermatitis Inflammatory Disorders Inflammatory Disease Janus Kinase Inhibitor Chemo
Is CCXI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 14.51
52 Week Low 9.07
Average Volume 366,597
200-Day Moving Average 11.3996
50-Day Moving Average 11.263
20-Day Moving Average 10.627
10-Day Moving Average 10.624
Average True Range 0.5409
ADX 18.98
+DI 25.1265
-DI 21.6651
Chandelier Exit (Long, 3 ATRs ) 10.0373
Chandelier Exit (Short, 3 ATRs ) 11.5327
Upper Bollinger Band 11.3636
Lower Bollinger Band 9.8904
Percent B (%b) 0.69
BandWidth 13.862802
MACD Line -0.0873
MACD Signal Line -0.1701
MACD Histogram 0.0828
Fundamentals Value
Market Cap 531.38 Million
Num Shares 48.7 Million
EPS -0.62
Price-to-Earnings (P/E) Ratio -17.60
Price-to-Sales 12.42
Price-to-Book 7.97
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.80
Resistance 3 (R3) 11.74 11.39 11.65
Resistance 2 (R2) 11.39 11.16 11.42 11.60
Resistance 1 (R1) 11.15 11.03 11.27 11.21 11.55
Pivot Point 10.80 10.80 10.86 10.83 10.80
Support 1 (S1) 10.56 10.57 10.68 10.62 10.27
Support 2 (S2) 10.21 10.44 10.24 10.22
Support 3 (S3) 9.97 10.21 10.17
Support 4 (S4) 10.03